[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100541300":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":24,"centralContacts":27,"locations":33,"responsibleParty":54,"collaborators":24,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":24,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":24,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":78,"overallStatus":35,"whyStopped":24,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Thammasat University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Mirogabalin","EXPERIMENTAL","Participants will receive 5 mg of mirogabalin, taken as half a tablet, every day twice a day, after breakfast and dinner, for 6 weeks.",[13],"Drug: Mirogabalin",{"label":15,"type":16,"description":17,"interventionNames":18},"Pregabalin","ACTIVE_COMPARATOR","Participants will receive 50 mg of pregabalin, taken as a tablet, every day twice a day, after breakfast and dinner, for 6 weeks.",[19],"Drug: Pregabalin",[21,25],{"type":22,"name":9,"description":11,"armGroupLabels":23,"otherNames":24},"DRUG",[9],null,{"type":22,"name":15,"description":17,"armGroupLabels":26,"otherNames":24},[15],[28],{"name":29,"role":30,"phone":31,"phoneExt":24,"email":32},"Yot Tanariyakul, M.D.","CONTACT","+66863930257","y.tanariyakul@gmail.com",[34],{"facility":5,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"RECRUITING","Khlong Luang","Changwat Pathum Thani","12120","Thailand","TH",{"type":42,"coordinates":43},"Point",[44,45],100.64578,14.06467,{"lat":45,"lon":44},[48,50,52],{"name":29,"role":30,"phone":49,"phoneExt":24,"email":32},"6683930257",{"name":29,"role":51,"phone":24,"phoneExt":24,"email":24},"PRINCIPAL_INVESTIGATOR",{"name":53,"role":51,"phone":24,"phoneExt":24,"email":24},"Krit Boontanapibul, M.D.",{"type":51,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"Yot Tanariyakul","Principle investigator","100541300","comparing-efficiency-of-mirogabalin-and-pregabalin-in-primary-tka-100541300",false,"NCT06328062","Comparing Efficiency of Mirogabalin and Pregabalin in Primary TKA","Comparison Efficacy of Mirogabalin and Pregabalin in Total Knee Arthroplasty. a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age 50-85 years old\n2. Unilateral primary osteoarthritis undergoing primary TKA\n3. ASA I-III\n\nExclusion Criteria:\n\n1. GFR \\<60\n2. Allergy to drug in this study\n3. Cannot underwent spinal anesthesia and adductor canal block\n4. Taking gabapentinoid within 3 months before surgery\n5. History of previous knee surgery\n6. Severe liver disease","ALL","50 Years","85 Years",{"count":68,"type":69},80,"ESTIMATED","INTERVENTIONAL",[72],"NA","The goal of this RCT is to compare efficacy between mirogabalin and pregabalin in pain reducing after unilateral primary total knee arthroplasty.\n\nThe main question\\[s\\] it aims to answer are:\n\n• Does mirogabalin have better pain reduction than pregabalin after unilateral primary total knee arthroplasty.\n\nParticipants will randomized to mirogabalin or pregabalin group and will take the drug for 6 weeks after TKA. Researchers will compare to pregabalin group to see pain and functional outcomes after TKA.",[75,76,77],"Pain Postoperative","Osteoarthritis","Total Knee Arthroplasty",[79,80,81,82],"mirogabalin","pregabalin","pain postoperative","TKA","2025-04-05",{"date":85,"type":86},"2025-04-09","ACTUAL",{"date":88,"type":86},"2024-04-01",{"date":90,"type":69},"2025-05-31",{"name":5,"class":6},1]